Gastrointestinal Cancer

The FDA granted an orphan drug designation to the oral investigational modified proprietary tyrosine derivative SM-88 as a treatment for patients with pancreatic cancer.

Ripretinib has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive disease.

Tanios S. Bekaii-Saab, MD, discusses how the field of gastrointestinal cancers is gaining ground with regard to the development of targeted and immunotherapy agents.

Syma Iqbal, MD, discusses the strategies used for the first-line treatment of patients with pancreatic cancer, options for later-line settings, and research efforts being made with targeted therapies.

Anthony B. El-Khoueiry, MD, discusses the evolution of HCC treatment, paradigm-shifting trials, and where future research is headed.

Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.

Jaffer A. Ajani, MD, discusses the potential clinical implications of fam-trastuzumab deruxtecan-nxki in gastric or gastroesophageal junction adenocarcinoma if approved by the FDA.

Experts share their insight on the efficacy and safety of trastuzumab deruxtecan in the gastric cancer space.

Daniel H. Ahn, DO, discusses the slew of actionable alterations that have emerged in colorectal cancer in recent years, including targeted therapies that are boosting survival outcomes.

Tanios S. Bekaii-Saab, MD, FACP, discusses the rapidly changing hepatocellular carcinoma treatment landscape and shares advice on how he navigates among the available options available for these patients.

Madappa Kundranda, MD, PhD, discusses the significance of the NAPOLI-1 and NAPOLI-3 trials in pancreatic cancer, other exciting ongoing research efforts, and key challenges remaining in the space.

Ghassan K. Abou-Alfa, MD, discusses the questions that remain with infigratinib in advanced cholangiocarcinoma with FGFR2 gene fusions/translocations.

In light of the COVID-19 pandemic, many elective surgical procedures had been cancelled or rescheduled to maximize hospital capacity and prevent unnecessary exposure for patients, but surgical delays might lead to worse outcomes for certain patients with gastrointestinal cancers.

Harry H. Yoon, MD, discusses how second-line pembrolizumab, followed by any subsequent therapy is associated with longer overall survival in patients with advanced gastric/gastroesophageal junction cancer.

The independent data monitoring committee has recommended that Celsion Corporation consider stopping the global, phase 3 OPTIMA trial examining ThermoDox® in combination with radiofrequency ablation for the treatment of patients with hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Andrew L. Coveler, MD, discusses the early-phase data with AMG 510 and AbGn-107 in gastrointestinal malignancies.

The treatment landscape of advanced hepatocellular carcinoma has been subject to rapid development in the last few years, says Amit G. Singal, MD, MS.

Shubham Pant, MD, discusses key data that emerged in the gastrointestinal oncology space from the 2020 ASCO Virtual Scientific Program.

The FDA has issued a complete response letter to Merck and Eisai stating that it will not approve the applications that are seeking the accelerated approval of pembrolizumab in combination with lenvatinib for the frontline treatment of patients with unresectable hepatocellular carcinoma.

Tanios S. Bekaii-Saab, MD, FACP, discusses second-line treatment options in hepatocellular carcinoma.

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

The European Commission has approved single-agent olaparib as a maintenance treatment for adult patients with germline BRCA1/2-mutant metastatic pancreatic adenocarcinoma who have not progressed after a minimum of 16 weeks of a frontline platinum-based chemotherapy regimen.

Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.

Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.